Business Context and Reporting Period
This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on July 15, 2013. The report discloses a material event under Regulation FD regarding the Company's collaboration with Teva Pharmaceutical Industries on the drug candidate RX-3117.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure event and does not contain financial statements.
Material Changes and Developments
- IND Submission: Teva Pharmaceutical Industries submitted an Investigational New Drug (IND) application to the FDA for RX-3117, a novel oral small molecule chemotherapy agent.
- Agreement Status: The submission is based on a Research and Exclusive License Option Agreement between Rexahn and Teva dated June 26, 2009.
- Clinical Progress: An exploratory Phase I trial completed in Europe in August 2012 demonstrated oral bioavailability with no reported adverse events. A further Phase I trial is expected to begin in the second half of 2013.
Outlook, Risks, and Management Commentary
Management anticipates the initiation of a further Phase I clinical trial in cancer patients during the second half of 2013. The filing notes that the information contained in the press release is not deemed filed for purposes of the Securities Exchange Act of 1934 unless expressly incorporated by reference.
Investor Verification Checklist
- Verify the status of the IND application for RX-3117 with the FDA.
- Confirm the specific terms and potential milestone payments within the 2009 agreement with Teva.
- Monitor the timeline for the initiation of the next Phase I clinical trial.
- Review the full text of the press release attached as Exhibit 99.1 for additional details.